# US 2014/0243274 A1 · Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0243274 A1
- Document ID: US20140243274A1
- Status: Published application
- Kind: A1
- Application number: 14/257,255
- Filed: 2014-04-21
- Published: 2014-08-28
- Earliest claimed: 2009-06-18
- Assignees: Strongbone AB
- Applicants: Strongbone AB
- Inventors: Anders GRUBB; Franciszek KASPRZYKOWSKI; Ulf LERNER; Beata ZOLNOWSKA; Regina KASPRZYKOWSKA
- Web page: https://patentgrep.com/patent/US20140243274A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07K 5/06: Dipeptides
- C07K 5/06043: {Leu-amino acid}
- C07K 5/06052: {Val-amino acid}
- C07K 5/06095: {Arg-amino acid}
- C07K 5/08: Tripeptides
- C07K 5/10: Tetrapeptides
- C07K 5/1016: {and aromatic or cycloaliphatic}
- C07K 5/1019: {with the first amino acid being basic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds of formula R1-A-NH—CH(R2)—CO—R3 are presented. The compounds can be used to treat or alleviate conditions associated with bone loss or low bone density, or to inhibit osteoclast differentiation and stimulation, bone resorption and/or loosening of a prosthetic device. The compounds can be administered as a pharmaceutical composition or in a prosthetic device.

## Claims

### Claim 1

A method of treating a condition associated with bone loss or low bone density or for inhibiting osteoclast differentiation and stimulation, bone resorption, or loosening of a prosthetic device in a mammal, comprising administering to said mammal an effective amount a compound or combination of compounds of the general formula (I)
R1-A-NH—CH(R2)—CO—R3 (1)
wherein,
R1 is NH2—C(NH)—NH—(CH2)m—CO, an acyl residue containing a hydroxylated coumarin moiety, or Ar—N—, where X is (CH2)m—O—CO, (CH2)m—SO2—CH═CH—CO, CH═CH—CO, CO-oxirane-CO, CO—CH═CH—CO, CH2—CH═CH—CO or (CH2)m—CO, and m is an integer of 0 to 5;
A is a bond or is one or more of Arg, Val or Leu;
R2 is isopropyl or isobutyl; and
R3 is NH—(CH2)m—NH—C(NH)—NH2, Phe-NH2, or NH—CH(R4) (CH2)m—NH-D, where R4 is a C1-C6 alkyl and D is CO—CH═CH—Ar, CO—CH═CH—SO2—(CH2)m—Ar, or Cum-Phe-, where Ar is aryl or heteroaryl, Cum is an acyl residue containing hydroxylated coumarin moiety, and m is an integer of 0 to 5;
the compound being a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound is selected from the group consisting of:
the compound being a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the compound is selected from the group consisting of: A-20, A-25, A-26, A-30, A-33, A-47, A-49, A-50, A-54, and A-59.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the compound is selected from group consisting of: A-59, A-107, A-116, A-118, A-119, A-120, A-123, A-127 and A-128.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the compound is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier, buffer, excipient or diluent.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is administered in a prosthetic device.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the condition is a bone disease selected from the group consisting of osteoporosis, juvenile osteoporosis, osteogenesis imperfecta, hypercalcaemia, hyperparathyroidism, osteomalacia, osteohalisteresis, osteolytic bone disease, osteonecrosis and Paget's disease of bone, or the condition is a secondary osteoporosis of bone loss due to rheumatoid arthritis, inflammatory arthritis, osteomyelitis, bone loss due to an eating disorder, metastatic bone diseases, periodontal bone loss, bone loss due to cancer, age-related loss of bone, or bone resorption induced by pharmaceuticals or implants.

### Claim 8 (depends on 1)

A method of treating a subject suffering from a high level of bone resorption, comprising administering to the subject an effective amount of the compound or combination of compounds according to claim 1.

### Claim 9 (depends on 1)

A method of inhibiting osteoclast formation or activity in a subject in need thereof, comprising administering to the subject an effective amount of the compound or combination of compounds according to claim 1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the subject is suffering from osteoporosis.
